<qa>  What is the proposed Phase II dosage of the investigational drug IMO 2055?To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055 when combined with erlotinib and bevacizumab in patients with previously treated advanced NSCLC. 